Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Tian Zhang, MD, explains how to treat mRCC after combination I-O in the 1st line setting

Dr. Zhang, Assistant Professor of Medicine, Duke Cancer Institute, explains how to treat metastatic renal cell carcinoma (mRCC) after combination I-O in the 1st line setting

Published: 22 February 2019

Recent Videos: Kidney (Renal Cell) Cancer

video

Tian Zhang, MD, explains how to treat mRCC after combination I-O in the 1st line setting

Dr. Zhang, Assistant Professor of Medicine, Duke Cancer Institute, explains how to treat metastatic renal cell carcinoma (mRCC) after combination ...

video

Michael Atkins, MD, considers how to treat mRCC after combination I-O in the 1st line setting

Dr. Atkins, Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology, Georgetown University Medical Center, ...

video

Tian Zhang, MD, discusses intermediate/poor and favorable risk RCC patients

Dr. Zhang, Assistant Professor of Medicine, Duke Cancer Institute, explains how we may treat intermediate/poor risk renal cell cancer ...

video

Michael Atkins, MD, considers intermediate/poor & favorable risk RCC patients

Dr. Atkins, Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology, Georgetown University Medical Center, ...

video

Tian Zhang, MD, elaborates on the outcomes of KEYNOTE 426 presented at GU 2019

Dr. Zhang, Assistant Professor of Medicine, Duke Cancer Institute, shares outcomes from the KEYNOTE 426 Phase III study investigating ...

video

Tian Zhang, MD, on predictive biomarkers in selecting patient populations for I-O treatment in RCC

Dr. Zhang, Assistant Professor of Medicine, Duke Cancer Institute, discusses relevant predictors of outcomes for immunotherapy treatment in metastatic renal ...

video

Rana McKay, MD, explains how to differentiate between TKIs available for renal cell cancer patients

Dr. McKay, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, describes how to differentiate between the various ...

video

Rana McKay, MD, on next steps when treating mRCC patients who receive I-O in the front line space

Dr. McKay, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, considers how to treat patients with metastatic ...

video

Rana McKay, MD, offers impressions of the TIVO-3 study in highly refractory advanced RCC patients

Dr. McKay, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, shares thoughts on the outcomes from the ...

video

Rana McKay, MD, on recent data examining atezolizumab and bevacizumab in nccRCC & sccRCC

Dr. McKay, Medical Oncologist, Assistant Professor of Medicine, University of California, San Diego, offers opinion on whether the results of ...

Related Videos

video-image

Michael Atkins, MD, considers how to treat mRCC after combination I-O in the 1st line setting

video-image

Tian Zhang, MD, discusses intermediate/poor and favorable risk RCC patients

video-image

Michael Atkins, MD, considers intermediate/poor & favorable risk RCC patients

video-image

Tian Zhang, MD, elaborates on the outcomes of KEYNOTE 426 presented at GU 2019

video-image

Tian Zhang, MD, on predictive biomarkers in selecting patient populations for I-O treatment in RCC

video-image

Rana McKay, MD, explains how to differentiate between TKIs available for renal cell cancer patients

video-image

Rana McKay, MD, on next steps when treating mRCC patients who receive I-O in the front line space

video-image

Rana McKay, MD, offers impressions of the TIVO-3 study in highly refractory advanced RCC patients

video-image

Rana McKay, MD, on recent data examining atezolizumab and bevacizumab in nccRCC & sccRCC

video-image

Rana McKay, MD, considers the implications of CHECKMATE 214 & KEYNOTE-426 presented at GU 2019

video-image

Rana McKay, MD, elaborates on the outcomes of the KEYNOTE 426 Phase III study in mRCC

video-image

Michael Atkins, MD, offers opinion on IO-TKI combinations in renal cell cancer

video-image

Michael Atkins, MD, regarding the KEYNOTE 426 Phase III trial in metastatic renal cell carcinoma

video-image

Richard Finn, MD, outlines the role of TACE with systemic therapy in HCC

video-image

Richard Finn, MD, considers the effectiveness of sorafenib + I-O in newly diagnosed HCC

video-image

Raymond Wadlow, MD, on surrogate biomarkers in the treatment of hepatocellular carcinoma

video-image

Richard Finn, MD, elaborates on current treatment options & sequencing of TKIs in HCC

video-image

Zev Wainberg, MD, regarding the results of the ROAR basket trial from GI 2019

video-image

Raymond Wadlow, MD, speculates on the use of TKIs in the management of HCC

video-image

Zev Wainberg, MD, considers regorafenib in locally advanced biliary tract cancer

video-image

Richard Finn, MD, speculates on combined checkpoint inhibition in HCC & biliary tract cancer

video-image

Richard Finn, MD, shares his thoughts on the role of systemic therapy in HCC

video-image

Rachna Shroff, MD, on the utilization of TKIs in treatment of hepatocellular carcinoma

video-image

Richard Kim, MD, shares how we can utilize TKIs in the management of hepatocellular carcinoma

video-image

Andrew X. Zhu, MD, PhD, considers whether sorafenib is tolerable in combination with I-O in HCC

video-image

Andrew X. Zhu, MD, PhD, on what physicians should know about sequencing TKIs in HCC

video-image

Andrew X. Zhu, MD, PhD, regarding checkpoint inhibitors in advanced HCC

video-image

Alan Venook, MD, shares key takeaways from GI 2019 regarding the treatment of biliary tract cancers

video-image

Alan Venook, MD, on the latest in identifying valid biomarkers in the treatment of HCC

video-image

Nevena Damjanov, MD, regarding the impact of the ReDOS study in HCC

video-image

Nevena Damjanov, MD, elaborates on stereotactic body radiation therapy in early stage HCC

video-image

Nevena Damjanov, MD, regarding sequencing TKIs in hepatocellular carcinoma (HCC)

video-image

Nevena Damjanov, MD, shares thoughts on the role of systemic therapy in HCC

video-image

Robert A. Figlin, MD, on the convenience factor of oral TKIs & treatment decisions in advanced RCC

video-image

Robert A. Figlin, MD, on the trade-offs between safety & efficacy when discussing 1st line RCC

video-image

Robert A. Figlin, MD, provides perspective on I-O failures

video-image

Robert A. Figlin, MD, on deciding which metastatic RCC patients should get a TKI as 1st line therapy

video-image

Robert A. Figlin, MD, on how checkpoint inhibitors figure into treatment for 1st line RCC patients

video-image

Walter Stadler, MD, regarding TKIs in the treatment of renal cell carcinoma

video-image

Walter Stadler, MD, on treating RCC in the 2nd line setting following I-O failure

video-image

Walter Stadler, MD, considers which mRCC patients should receive a TKI as 1st line therapy

video-image

David I. Quinn, MD, provides perspective on the trade-offs between safety & efficacy in 1st line RCC

video-image

David I. Quinn, MD, considers whether the convenience of oral TKIs impacts RCC treatment

video-image

David I. Quinn, MD, comments on 2nd line therapy options following I-O failure

video-image

David I. Quinn, MD, shares thoughts on Keynote 427 from the 2018 ASCO Annual Meeting

video-image

David I. Quinn, MD, regarding the most exciting RCC data coming out of ASCO 2018

video-image

Jeanny B. Aragon-Ching, MD, FACP, shares how checkpoint inhibitors fit into RCC treatment algorithms

video-image

Jeanny B. Aragon-Ching, MD, FACP, comments on 2nd line treatment options in RCC after I-O failure

video-image

Ghassan Abou-Alfa, MD, MBA, regarding the shortcomings of the RECIST study in HCC

video-image

Ghassan Abou-Alfa, MD, MBA, shares the outcomes of the CELESTIAL study from ASCO 2018

video-image

Ghassan Abou-Alfa, MD, MBA, considers how immunotherapies should be combined with TKIs

video-image

Ghassan Abou-Alfa, MD, MBA, on the latest in systemic therapy for advanced HCC

video-image

Primo N. Lara, Jr., MD, comments on which TKIs appear most effective in 1st line RCC

video-image

Primo N. Lara, Jr., MD, on whether the convenience of oral TKIs influences treatment decisions

video-image

Primo N. Lara, Jr., MD, considers the trade-offs between safety & efficacy in 1st line RCC treatment

video-image

Primo N. Lara, Jr., MD, regarding the treatment path following I-O failure

video-image

Primo N. Lara, Jr., MD, on deciding which mRCC patients should receive a TKI

video-image

Primo N. Lara, Jr., MD, on how checkpoint inhibitors fit into RCC treatment algorithms

video-image

Brian I. Rini, MD, FACP, comments on the CARMENA study presented at ASCO 2018

video-image

Brian I. Rini, MD, FACP, discusses the influence of the convenience of oral TKIs

video-image

Brian I. Rini, MD, FACP, regarding the trade-offs between safety & efficacy in 1st line RCC

video-image

Brian I. Rini, MD, FACP, considers 2nd line treatment in advanced RCC following I-O failure

video-image

Brian I. Rini, MD, FACP, on which metastatic RCC patients should receive a TKI as 1st line therapy

video-image

Brian I. Rini, MD, FACP, on how checkpoint inhibitors figure into treatment algorithms for RCC

video-image

David I. Quinn, MD, on which metastatic RCC patients should receive a TKI as first-line therapy

video-image

Nicholas Vogelzang, MD, FASCO, FACP, regarding sipuleucel-T in mCRPC

video-image

Tian Zhang, MD, on whether patients in the 1st line setting should receive a single agent TKI

video-image

Nicholas Vogelzang, MD, FASCO, FACP, elaborates on combining checkpoint inhibitors in mCRPC

video-image

Michael Atkins, MD, regarding single agent TKIs in the 1st line setting

video-image

Nicholas Vogelzang, MD, FASCO, FACP, regarding combination pembrolizumab and olaparib in mCRPC

video-image

Nicholas Vogelzang, MD, FASCO, FACP, offers his impression of KEYNOTE 365 in mCRPC

video-image

Nicholas Vogelzang, MD, FASCO, FACP, regarding the evolution of ADT in prostate cancer

video-image

Nicholas Vogelzang, MD, FASCO, FACP, on the evolving treatment landscape of nmCRPC

video-image

Evan Yu, MD, considers when sipuleucel-T should be used in treatment of mCRPC

video-image

Evan Yu, MD, on combining checkpoint inhibitors in metastatic castration-resistant prostate cancer

video-image

Sumit K. Subudhi, MD, PhD, discusses combining checkpoint inhibitors in mCRPC

video-image

Evan Yu, MD, regarding combination pembrolizumab and olaparib in mCRPC

video-image

Sumit K. Subudhi, MD, PhD, on when sipuleucel-T should be used in treatment of mCRPC

video-image

Evan Yu, MD, elaborates on the results from KEYNOTE 365 in mCRPC

video-image

Bridget F. Koontz, MD, speculates on the evolving landscape of prostate cancer

video-image

Sumit K. Subudhi, MD, PhD, considers the outcomes of the KEYNOTE 365 study

video-image

Bridget F. Koontz, MD, regarding new guidelines on hypofractionated EBRT in prostate cancer

video-image

Tomasz Beer, MD, regarding the ARAMIS study in nmCRPC from GU 2019

video-image

Bridget F. Koontz, MD, on moderate hypofractionation & ultra-hypofractionation in prostate cancer

video-image

Tomasz Beer, MD, elaborates on recent data utilizing LuPSMA in men with mCRPC

video-image

William Oh, MD, discusses the evolving treatment landscape for patients with nmCRPC

video-image

William Oh, MD, tells us how PSA is valuable as a biomarker in the treatment of prostate cancer

video-image

William Oh, MD, discusses recent data examining LuPSMA in men with mCRPC

video-image

William Oh, MD, regarding data on racial differences in response to novel prostate cancer therapies

video-image

Yair Lotan, MD, considers the role of checkpoint inhibitors in bladder cancer

video-image

Yair Lotan, MD, shares outcomes of KEYNOTE 057 in high-risk non-muscle-invasive bladder cancer

video-image

Mark T. Fleming, MD, regarding the implications of the CHECKMATE 650 study presented at GU 2019

video-image

Yair Lotan, MD, on the challenges using biomarkers for treatment selection in bladder cancer

video-image

Mark T. Fleming, MD, regarding the Aramis study in prostate cancer

video-image

Yair Lotan, MD, on molecular characterization & subtyping data in bladder cancer

video-image

Mark T. Fleming, MD, offers his impression of the LATITUDE study in NDx-HR mCNPC

video-image

Yair Lotan, MD, considers the latest in screening for high-risk asymptomatic bladder cancer

video-image

Mark T. Fleming, MD, on the ARCHES trial in metastatic hormone-sensitive prostate cancer

video-image

Andrew Armstrong, MD, offers opinion on androgen receptor inhibitors

video-image

Andrew Armstrong, MD, discusses the Phase 2 STREAM study in pre-metastatic prostate cancer

video-image

Andrew Armstrong, MD, presents an overview of the ARCHES trial in mHSPC